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Friedreich ataxia (FA) is a progressive neurodegenerative disease caused by expansion of a trinucleotide repeat
within the ﬁrst intron of the gene that encodes frataxin. In our study, we investigated the regulation of frataxin
expression by iron and demonstrated that frataxin mRNA levels decrease signiﬁcantly in multiple human cell
lines treated with the iron chelator, desferal (DFO). In addition, frataxin mRNA and protein levels decrease in
ﬁbroblast and lymphoblast cells derived from both normal controls and from patients with FA when treated
with DFO. Lymphoblasts and ﬁbroblasts of FA patients have evidence of cytosolic iron depletion, as indicated
by increased levels of iron regulatory protein 2 (IRP2) and/or increased IRE-binding activity of IRP1. We postu-
late that this inferred cytosolic iron depletion occurs as frataxin-deﬁcient cells overload their mitochondria with
iron, a downstream regulatory effect that has been observed previously when mitochondrial iron–sulfur cluster
assembly is disrupted. The mitochondrial iron overload and presumed cytosolic iron depletion potentially
further compromise function in frataxin-deﬁcient cells by decreasing frataxin expression. Thus, our results
imply that therapeutic efforts should focus on an approach that combines iron removal from mitochondria
with a treatment that increases cytosolic iron levels to maximize residual frataxin expression in FA patients.
INTRODUCTION
Friedreich ataxia (FA) is a progressive disease caused by
expansion of a GAA trinucleotide repeat in the gene that
encodes frataxin. Patients develop ataxia, sensory loss and car-
diomyopathy, and symptoms are limited mainly to the central
nervous system and heart (reviewed in 1,2). Frataxin is import-
ant in iron–sulfur cluster assembly where it likely functions as
a chaperone that provides iron in a bioavailable form in the
early steps of iron–sulfur cluster biosynthesis (reviewed in
3). Patients manifest mitochondrial iron–sulfur cluster assem-
bly deﬁciency, with decreased activity of iron–sulfur proteins
such as mitochondrial aconitase and succinate dehydrogenase.
As disease progresses, mitochondrial iron overload develops
in the heart and central nervous system (4–6). Because of
the mitochondrial iron overload, it has been considered that
iron chelation therapy should ameliorate disease by protecting
mitochondria from the adverse effects of iron overload.
Studies in tissue culture performed with the primarily
cytosolic iron chelator, desferal (DFO) (7), or with lipophilic
iron chelators that speciﬁcally target mitochondrial iron,
including pyridoxal isonicotinoyl hydrazone and analogues of
2-pyridylcarboxaldehyde isonicotinoyl hydrazone (8,9), as
well as studies in patients using deferiprone, a membrane-
permeable chelator thought to be capable of shuttling chelated
iron from cells to transferrin (10) have shown positive results.
Although many chelator studies have been performed on FA
cells and models, none has evaluated the effects of iron chela-
tion on levels of residual frataxin expression in patients. Low
expression of FXN causes iron accumulation in mitochondria,
a common phenotype observed when proteins involved in
iron–sulfur cluster biogenesis are deﬁcient (11). Previous
studies have shown that yeast which lacks the mitochondrial
ABC transporter, Atm1 (a homologue of human ABCB7),
display features of both mitochondrial iron overload and cyto-
solic iron starvation (12), which is similar to the phenotype of
frataxin-deﬁcient yeast (13). Interestingly, levels of yfh1 (fra-
taxin) mRNA level decreased 4-fold in Atm1-deﬁcient yeast,
whereas atm1 mRNA levels were unchanged in the yfh1
mutant (12). Although this study suggested that yfh1 levels
were regulated by iron, the authors were unable to conﬁrm
iron-dependent regulation of frataxin when they manipulated
iron levels in yeast.
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iron–sulfur scaffold protein, ISCU, decreases with iron chela-
tion (14), we decided to evaluate the effects of iron depletion
on frataxin expression. We treated human cell lines with the
iron chelator, DFO, or the iron salt, ferric ammonium citrate
(FAC), to determine whether frataxin expression changes in
normal controls or in cell lines derived from FA patients.
We discovered that frataxin mRNA levels decrease signiﬁ-
cantly in multiple human cell lines treated with DFO. In
addition, frataxin levels decrease in ﬁbroblasts and lympho-
blast cells derived from both normal controls and from patients
with FA when treated with DFO. Using activity of iron regu-
latory proteins as an indicator of cytosolic iron status, we ﬁnd
evidence to support that there is cytosolic iron depletion in
ﬁbroblast and lymphoblast cell lines from FA patients com-
pared with normal control cell lines. Our results suggest that
cytosolic iron depletion may worsen FA by further diminish-
ing expression of frataxin.
RESULTS
To study whether frataxin expression was regulated by iron, we
studiedhumancelllines,includingHEK293.Afteraddingeither
FAC or the iron chelator DFO (Sigma) to cells for 16 h, we
observed that frataxin mRNA levels decreased in cells treated
with DFO, as detected by northern blot (Fig. 1A) and conﬁrmed
by quantitative real-time PCR (qRT–PCR) (Fig. 1B). In
addition to ﬁnding the major frataxin transcript of 1.24 kb as
previously reported (15), we observed some similarly regulated
bands (e.g. 1.7 and 2.3 kb), whereas some others did not
appear to be regulated (e.g 3.2, 4.5 and 5.8 kb bands). All of
these bands were detected using an antisense RNA probe to
the sense strand of FXN, and we do not know whether the
larger weak bands are non-speciﬁc, or whether they represent
different isoforms or incompletely spliced intermediate forms.
We also tested ﬁbroblast cell lines (GM08399, Coriell Cell
Repositories), and found increased mRNA levels of frataxin in
cells treated with FAC versus DFO (Fig. 1C), which was con-
ﬁrmed by qRT–PCR (Fig. 1D). This decrease in frataxin
expression with DFO treatment was also observed in other
cell lines we tested, including the rhabdomyosarcoma cell
line, RD4 (data not shown).
To evaluate the mechanisms of regulation of FXN mRNA
levels by iron status, we cloned the previously deﬁned
human frataxin promoter region (16,17), and generated con-
structs that incorporated 1.2 (luc 1), 1.8 (luc 2) or 3.2 kb
(luc 3) upstream of the ﬁrst AUG of exon 1 into a luciferase
reporter plasmid, as described previously (17). In another con-
struct (pGL-GAA-luc), we fused a DNA fragment including
the promoter region (1.3 kb upstream of the ﬁrst AUG in
exon 1), the entire ﬁrst exon, and 1.2 kb of the 50 end of the
Figure 1. Frataxin (FXN) mRNA expression is regulated by iron status in human cell lines. HEK293 cells were treated with desferal (DFO, 100 mM), normal
unsupplemented medium (Ctr) or ferric ammonium citrate (FAC, 200 mM) for 16 h. (A) mRNA levels of FXN decreased in DFO treated cells compared with
control (Ctr) and FAC treated cells. Equal loading was veriﬁed by GAPDH and L32 measurements. (B) Quantitative real-time PCR (qRT–PCR) was carried out
for FXN and mRNA levels decreased signiﬁcantly (P ¼ 0.0013) after DFO treatment. (C) Northern analysis and (D) qRT–PCR were carried out for FXN on
ﬁbroblasts (GM08399) derived from a normal control, treated either with DFO (100 mM) or FAC (200 mM). Frataxin levels in qRT–PCR were signiﬁcantly
reduced (P ¼ 0.028). Ribosomal RNA levels (28S and 18S) were used as loading controls for (C) and GAPDH was used as an internal control for (D). (E)
Luciferase activity driven by FXN promoter decreased signiﬁcantly (P ¼ 0.0025) when the cells were treated with DFO compared with growth in normal iron-
replete media. The empty plasmid was used as a negative control. FXN-luc1, 2 and 3 contained different fragments of genomic DNA, and FXN-GAA-luc con-
tained the frataxin promoter, ﬁrst exon and a portion of the ﬁrst intron as described in Materials and Methods. Statistical analysis was done with the Student’s
t-test:  P , 0.05,   P , 0.01.
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expansion with luciferase. Each of the four constructs showed
that DFO treatment signiﬁcantly reduced the expression of
luciferase compared with untreated controls (Fig. 1E),
although the pGL4-GAA-luc construct showed lower promo-
ter activity.
To study whether frataxin protein levels were regulated by
iron,as expected based on mRNA results, we analyzed the half-
life of frataxin in metabolic labeling experiments to deﬁne the
optimal length of iron or iron chelator treatments. After
immunoprecipitation (IP) of frataxin radiolabeled with
35S-methionine, we observed the frataxin precursor and the fra-
taxin intermediate band generated during mitochondrial import
(Fig. 2A), but we were unable to observe the mature fully pro-
cessed product (Fig. 2D), as the mature form does not contain
methionine (18). There are two methionines in the unprocessed
frataxinprecursor,bothofwhichareremovedduringmitochon-
drial import. The inferred cleavage sites are indicated in
Figure 2D with inverted arrowheads (18,19), and methionines
are underlined. In order to measure the half-life of mature fra-
taxin in cells, we replaced two leucines (L) (amino acids
200th and 203rd) of frataxin, with methionine (M) (described
in Materials and Methods). Metabolic labeling results showed
that the half-life of the initial precursor was 10 min, whereas
that of the intermediate was 2 h 10 min, and that of the mature
form was 50 h (Fig. 2B and C).
We then analyzed regulation of frataxin mRNA and protein
levels in ﬁbroblast cell lines of controls and FA patients after
treatment with DFO or FAC for 48 h. We found that frataxin
mRNA levels decreased in ﬁbroblasts (GM03665) of patients
treated with DFO (Fig. 3A) and we veriﬁed this result with
qRT–PCR (Fig. 3B). We then veriﬁed that protein levels
changed in RD4 (top), HEK293 (middle), ﬁbroblasts
(GM04078 and GM03816, not shown) and lymphoblasts
(GM15850) from affected patients (bottom, Fig. 3C). The
increased levels of transferrin receptor and decreased levels
of ferritin H and L chains after DFO treatment in lymphoblasts
conﬁrmed that the iron treatment was efﬁcacious. Instan-
taneous biosynthetic rate measurements showed markedly
diminished biosynthesis of endogenous frataxin after treat-
ment with DFO (Fig. 3D), further conﬁrming regulation of fra-
taxin expression by iron.
To more fully characterize cellular iron status in cell lines
from FA patients, we compared ﬁbroblast and lymphoblast
cell lines derived from either normal controls or patients that
are either age and sex-matched, or proband and parent-paired,
Figure 2. Half-life determination of human FXN in HEK293 cells with metabolic labeling. (A) Endogenous FXN of HEK293 cells was chased and only the
precursor (p) and intermediate (i) forms were identiﬁed. (B) and (C) A mutagenized form of frataxin (FXN L200/203M- described in Materials and
Methods) was expressed in HEK293 cells to allow visualization of the mature isoform (m). The half life of human FXN was calculated from three independent
experiments, and precursor (p), intermediate (i) and mature (m) forms are represented in lower panels of (B and C) with the half-life of the mature form calcu-
lated as 50 h. (D) The amino acid sequence of the human FXN open reading frame. The initiator methionine and an in-frame methionine (M) are underlined.
The inverted arrowheads indicate proposed sites of cleavage associated with mitochondrial uptake. The ﬁrst two cleavage sites were initially proposed according
to molecular weight in a number of in vitro studies (19,43), whereas the third cleavage site of human endogenous FXN was identiﬁed by mass spectrometry (18).
The last two leucines (L) were replaced with methionine (M), underlined and in italics.
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(IRP2), IRE-binding activity and aconitase activities. Compar-
ing lymphoblasts from patients (P) to control (C) cell lines, we
found that frataxin expression levels varied from 8.5% [e.g.
the pair of GM16200 (C5) and GM16197 (P5) in Fig. 4A,
right column] to 25% [e.g. the pairs of GM16215 (C6) and
GM16214 (P6), AG15799 (C7) and GM16209 (P7), Fig. 4A,
right column] of control levels, whereas in ﬁbroblasts from
three different patients, we found that frataxin levels varied
from 10% [e.g. the pair of GM08399 (C3) and GM03665
(P3), Fig. 4A, left column] to 66% [e.g. the pair of
AG09429 (C2) and GM03816 (P2), Fig.4A, left column] of
normal control levels, quantiﬁed as described in Materials
and Methods. We found that without any iron manipulations,
lymphoblast cell lines of FA patients showed increased
levels of IRP2 in western blots (Fig. 4A) and RNA gel-shift
studies (Fig. 4B) compared with normal controls. In the pre-
sence of high iron and oxygen, IRP2 undergoes iron-
dependent degradation (20,21). Although low oxygen levels
and increased cobalt levels can stabilize IRP2, high IRP2
levels are in general an excellent indicator of cytosolic iron
status in mammalian cells (reviewed in 22). IRP2 was not
detectable in ﬁbroblasts, but gel-shift studies indicated that
the IRE-binding ability of IRP1 was markedly increased, as
has been previously observed in FA patient cells (23)
(Fig. 4B), as well as in RNAi knockdown studies in HeLa
cells (24) and in mouse models (25). In correlation, both mito-
chondrial and cytosolic aconitase activities were decreased in
patient ﬁbroblasts, and cytosolic aconitase activity was signiﬁ-
cantly decreased in lymphoblasts (Fig. 4C). Thus, IRP1 con-
verted from the cytosolic aconitase form to the IRE-binding
form without change of IRP1 protein levels in cell lines of
patients with FA.
To further verify the effects of iron on FXN expression, we
challenged the FA patient cells with different concentrations
of DFO or FAC. We observed regulation of FXN, as well as
sensitivity of FA ﬁbroblasts to iron depletion, where as little
as 1 or 2 mM DFO abolished cytosolic aconitase activity of
IRP1, and 10 mM DFO was sufﬁcient to dramatically decrease
mitochondrial aconitase activity (Fig. 5). In addition, the IRE-
binding activity of IRP1 and IRP2 were maximal at 5 mMo f
DFO concentration, suggesting that the cells of the FA patients
were relatively iron-starved prior to treatment.
In summary, our results demonstrated that cytosolic iron
depletion may contribute to decreased expression of frataxin in
FA patientsandmaytherebyworsen disease(modeledinFig. 6).
DISCUSSION
In this study, we have demonstrated that frataxin expression
levels are regulated by iron in various human tissue culture
cell lines, and in lymphoblasts and ﬁbroblasts from controls
Figure 3. Iron deprivation reduces FXN protein levels. Northern analysis (A) and qRT–PCR (B) were performed for FXN in ﬁbroblasts GM03665 derived from
an FA patient. Ribosomal RNAs (28S and 18S) were used as loading controls in (A) and GAPDH was used to normalize in (B), where frataxin levels were
signiﬁcantly reduced by treatment with desferal (  P ¼ 0.0006). (C) Immunoblots showed that FXN protein levels diminished with iron deprivation, observed
with DFO treatment in the rhabdomyosarcoma cell line RD4 (top), HEK293 cells (middle) and lymphoblasts from an FA patient (GM15850) (bottom). Trans-
ferrin receptor (TfR) and ferritin (H- and L subunits, H-Ft and L-Ft) were used to verify that iron treatments were efﬁcacious. (D) Biosynthetic labeling of FXN
was performed after cellular iron status was manipulated. HEK293 cells were treated with DFO (30 mM) or FAC (200 mM) for 48 h prior to labeling with
[
35S]-methionine at the indicated time points. Immunoprecipitation was performed using equal counts of radioactively labeled material.
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structs, we have further observed that transcriptional regu-
lation likely accounts for much of the iron-dependent
regulation of frataxin in controls. Importantly, signiﬁcant iron-
dependent regulation was also observed in the lymphoblast
and ﬁbroblast cell lines derived from FA patients. To further
evaluate the importance of iron-dependent regulation of fra-
taxin in patients, we analyzed cytosolic iron status by assaying
activity of IRP1 and IRP2. IRP1 and IRP2 are mammalian
proteins that register cytosolic iron concentrations and post-
transcriptionally regulate expression of numerous iron
metabolism genes to optimize cellular iron availability. IRP1
registers cytosolic iron status mainly through an iron–sulfur
cluster at its active site; when the iron–sulfur cluster is
present, IRP1 is an active cytosolic aconitase, whereas when
the cluster is absent, IRP1 becomes an apoprotein that under-
goes a signiﬁcant conformational change, enabling it to bind to
IREs, RNA stem-loop structures found within transcripts
(reviewed in 22,26,27). Although IRP2 is homologous to
IRP1, IRP2 activity is regulated primarily by iron-dependent
degradation through the ubiquitin-proteasomal system in iron-
replete cells (22,26,27). Targeted deletions of IRP1 and IRP2
in animals have demonstrated that IRP2 is the chief physio-
logic iron sensor in animals (28,29). Gel-shifts in this study
showed that the IRE-binding activities of both IRP1 and
IRP2 were increased in FA patient lymphoblasts, and IRP2
levels were increased relative to controls (Fig. 4), suggesting
that there is cytosolic iron depletion in FA cells. Our measure-
ments were not performed on the patient tissues that are very
adversely affected in FA, including the heart (6) and
Figure 4. Cell lines derived from FA patients show evidence of cytosolic iron depletion when grown under normal conditions. Either ﬁbroblasts (C1: GM08402
and P1:GM04078; C2:AG09429 and P2:GM03816; C3: GM08399 and P3: GM03665, left column) or lymphoblasts (C4: GM15849 and P4:GM15850, C5:
GM16200 and P5:GM16197, C6: GM16215 and P6:GM16214, C7: AG15799 and P7:GM16209, right column) derived from both healthy controls (C) and
FA patients (P) were compared. Representative results from multiple repetitions are shown here. Numbers 1–7 for controls and patients represent either age
and sex-matched (C1/P1, C2/P2, C3/P3, C4/P4, C7/P7) pairs or proband and parent-paired (C5/P5, C6/P6) pairs. (A) The relative protein levels of FXN,
IRP1 and IRP2 were determined by western blot, quantiﬁed as described in Materials and Methods. Both IRE-binding activities of IRP1 (white bar) and
IRP2 (grey bar) (B) and aconitase activities (C) (mitochondrial, m-aco, grey bar; cytosolic, c-aco, white bar) were assessed and quantiﬁed, showing signiﬁcant
decreases in aconitase activities ( P , 0.05), and increases in IRE binding activities (  P , 0.01).
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edly reduced, mitochondrial aconitase activity was normal in
lymphoblasts from a patient with only 10% of normal frataxin
levels, although cytosolic aconitase levels were signiﬁcantly
reduced (Fig. 4C, lanes C4 and P4, C5 and P5). Levels of
both cytosolic aconitase and mitochondrial aconitase were sig-
niﬁcantly reduced in FA ﬁbroblast cells in which frataxin
levels were 35% of normal (Fig. 4C, 30% for lane C1 and
P1, 66% for lane C2 and P2, 10% for lane C3 and P3), but
not as signiﬁcantly as has been reported in heart samples of
patients (30), consistent with the observation that disease
affects primarily heart and central nervous system, whereas
other tissues are less adversely affected.
Since we found evidence for cytosolic iron depletion in cell
types that do not develop phenotypes in FA, we postulate that
cytosolic iron depletion may be even more pronounced in
areas of the brain and heart that are functionally compromised
in FA patients. Interestingly, expression of ISCU was
decreased in the heart of frataxin-deﬁcient mice (31), and
cytosolic iron deﬁciency perhaps could explain the decrease
in ISCU expression (14). In the brain and heart of FA patients,
mitochondrial iron overload is prominent and is readily
detected with tissue iron stains. In numerous model systems,
mutations or deﬁciencies of iron–sulfur cluster biogenesis
proteins result not only in diminished activities of iron–
sulfur enzymes such as aconitase and succinate dehydrogen-
ase, but also in mitochondrial iron overload, which appears
to be a secondary effect that results from the compromise of
iron–sulfur cluster biogenesis (32) (reviewed in 11). Thus,
the cytosolic iron depletion that we observe in FA cells con-
forms to a pattern of compartmental iron misregulation
observed when iron–sulfur cluster biogenesis is impaired,
characterized by mitochondrial iron overload and cytosolic
iron depletion.
Therapeutic approaches to treatment of FA presently
include three broad areas: methods to increase frataxin
expression by decreasing heterochromatin formation at
the GAA repeat (33–35), methods to chelate iron and
thereby reduce associated oxidative stress (9) (10) and
methods to directly reduce oxidative stress (36), which
have recently been shown to be effective in a ﬂy model
for FA (37).
Since evidence in favor of cytosolic iron depletion has not
been previously reported in FA patients of cell lines, there
have been no efforts to increase cytosolic iron stores in
patients. Interestingly, several studies have reported that
adverse phenotypes can be ameliorated by treatment with
hemin, although the mechanism is unknown (38,39). Perhaps
hemin treatment increases frataxin expression by increasing
cytosolic iron levels, as we have observed in this study
when cells were treated with the iron salt, FAC (Figs 3C
and 5).
Our results imply that the proposed cytosolic iron depletion
that develops with frataxin deﬁciency may exacerbate disease
by further reducing frataxin transcription. Since we observed
that frataxin levels varied over at least a 2.5-fold range with
manipulations of iron, we suggest that frataxin expression
could potentially be increased signiﬁcantly in patients by judi-
cious management of iron status. We conclude that addition of
an iron supplementation regime that would replenish cytosolic
iron might be of value in conjunction with other therapeutic
approaches such as HDAC inhibitors (35), iron chelators that
would reduce mitochondrial iron stores (9,40), and antioxi-
dants that would mitigate the effects of mitochondrial iron
overload (36).
Figure 5. A titration curve of FA patient cells reveals that FA cells are mark-
edly affected by iron depletion, which further reduces FXN expression. Patient
lymphoblasts GM15850 were treated either with indicated concentrations of
DFO or with FAC for 60 h, then harvested, lysed and analyzed by the in-gel
aconitase assay, bandshift assay and western blot. The abbreviations are the
same as those used in Fig. 4.
Figure 6. A model of how cytosolic iron depletion decreases expression of fra-
taxin in FA patients and may thereby exacerbate disease. Frataxin deﬁciency
mainly caused by the triplet GAA repeat expansion in the ﬁrst intron of fra-
taxin gene leads to decreased frataxin expression and impairment of mitochon-
drial iron–sulfur cluster [Fe–S] assembly. Mitochondrial iron overload
develops as a consequence of deﬁcient [Fe–S] assembly in mitochondria
which leads to misregulation of mitochondrial iron homeostasis. Excess mito-
chondrial iron uptake and sequestration causes cytosolic iron depletion, which
can further diminish frataxin expression by decreasing frataxin transcription.
Thus, the decrease in frataxin levels caused by the trinucleotide repeat may
be worsened as cells accumulate mitochondrial iron and deplete cytosolic
iron stores. This negative feedback loop may contribute to progression of
disease in long-lived cells, particularly neurons and cardiomyocytes.
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Chemicals and cell cultures
FACanddeferoxamine(DFO,commercialname‘desferal’)were
purchase from Sigma (St Louis, MO). HEK293 cell line was
obtained from ATCC (Rockville, MD), lymphoblasts GM15851
and AG15799 (healthy), GM15849, GM16215 and GM16200
(unaffected carriers), GM15850, GM16209, GM16197,
GM16214andGM04079(FApatients),apparentlyhealthyﬁbro-
blasts,GM08399,AG09429andGM08402,andFApatientﬁbro-
blasts GM03665, GM03816 and GM04078 from the CoriellCell
Repostories(Camden,NJ).Allthemediumandantibiotics(when
necessary)wereboughtfromInvitrogen(Carlsbad,CA).Thecon-
dition for cultivation of the cells was followed according to the
instruction of the manufactories. Cells were incubated in a
humidiﬁed atmosphere of 5% CO2 at 378C.
Northern blot and qRT–PCR
Total RNA was isolated from 80% conﬂuence of cells after
treatment as needs with TRizol (Invitrogen). polyA RNA for
northern blot was isolated with PolyATract mRNA isolation
kit (cat# Z5210, Promega, Madison, WI). Northern hybridiz-
ation was carried out and the blot was exposed to Phospho-
Image screen and detected with Typhoon 9200 (GE
Healthcare). For qRT–PCR, 1 mg total RNA was used in the
reverse transcription reaction with random primers (Applied
Biosystems, cat# 4368814). Quantitative PCR was carried
out with a kit (Invitrogen, cat#11744). Primers for FXN gene
are: 50-CCTTGCAGACAAGCCATACA-30 and 50-CCAC
TGGATGGAGAAGATAG-30, for control GAPDH gene are:
50-TGCACCACCAACTGCTTAGC-30 and 50-GGCATG
GACTGTGGTCATGAG-30.
Plasmid construction and transfection
Wild-type full length of human frataxin gene coding for 210
amino acids was ampliﬁed with primers 50-AATCTCGAG
ATGGAAACTCTCGGGCGCCGCGCAGTAG-30 and 50-G
GGGGAAGCTTTCAAGCATCTTTTCCGGAATAGGCC-30,
then cloned into plasmid pcDNA3.1(2) with restriction sites
(XhoI and HindIII) to generate plasmid pcDNA3.1-mito-
hFRDA. Site-directed mutagenesis was carried out with Quik-
Change
w II Site-Directed Mutagenesis Kits (Stratagene, La
Jolla, CA) to mutate 200th and 203rd amino acid leucine (L)
into methionine (M) to produce plasmid pcDNA3.1-mito-
hFRDA L200/203M with primers 50-CCAAACTGGACAT
GTCTTCCATGGCCTATTCCGG-30 and 50-CCGGAATAG
GCCATGGAAGACATGTCCAGTTTGG-30. Plasmid trans-
fections were performed using Fugene6 (Roche Applied
Science, Indianapolis, IN) according to the manufactur0s
instructions. Stable cell line formation was conﬁrmed by
western and metabolic labeling.
Reporter gene assays
A template DNA construct FXN81658 (16) or a BAC con-
struct RP11-265B8 (BACPAC Resources Center, Oakland,
CA) was used to generate different promoter constructs for
cloning by PCR. Promoter fragments that extended 50 of the
initiation methionine of FXN exon 1 were cloned by adding
KpnI and NcoI sites to the PCR primers, and were then
inserted into pGL4.10[luc2] (Promega) (17). Cloned fragments
contained the 1.2 kb promoter region (16) for construct
FXN-luc1, a larger 1.8 kb fragment for FXN-luc2, or a
3.2 kb fragment in FXN-luc3. In addition, a fragment that con-
tained the promoter (1.3 kb), the entire ﬁrst exon, and the ﬁrst
1241 bases of intron 1 of human FXN was included in the
FXN-GAA-luc plasmid. For the FXN-GAA-luc plasmid, a
reverse primer containing the splice acceptor site from the 30
end of intron 1 and an NcoI site was designed so that the
FXN coding sequence in exon 1 would be translated in
frame with the luciferase open reading frame from
pGL4.10[luc2] (16). The four plasmids, generated as
FXN-luc1, FXN-luc2, FXN-luc3 and FXN-GAA-luc, were,
respectively, co-transfected with pGL4.75 into HEK293,
HeLa and RD4 cells. The luciferase assays were conducted
with Veritas microplate luminometer (Turner Biosystems,
Sunnyville, CA) according to the manufacturer’s manual
(Promega, cat#TM040). To control for transfection efﬁciency
in each well, ﬁreﬂy luciferase activity was normalized to
Rellina luciferase activity.
Metabolic labeling
HEK293 cells and stably transfected HEK293 with
pcDNA3.1-mito-hFRDA L200/203M were cultivated to
reach conﬂuence 80%, then labeled with [
35S]-methionine
(Perkin Elmer, Waltham, MA) for 1 h. After radiolabeling,
the cells were chased. Harvested cells were lysed, followed
by IP with antibody against human frataxin (MitoScience,
Eugene, OR). After the ﬁrst IP, a second IP (recapture) was
performed as previously described (41).
Western blot
Western blot analysis was performed as previously described
(42), using the above-described frataxin antibody. IRP1
and IRP2 antibodies were polyclonal, raised from rabbit
(29,14). H- and L-ferritin antibodies against human spleen
ferritin were purchased from Santa Cruz Biotech Inc.
(Santa Cruz, CA), transferrin receptor antibody from Zymed
(San Francisco, CA), a-tubulin and actin antibodies from
Sigma. Quantiﬁcation of the density of the western bands
was done with program ImageJ (http://rsb.info.nih.gov/ij/).
RNA mobility shift and in-gel aconitase activity assays
Gel retardation assays that separate human IRP1 and IRP2 and
in-gel aconitase activity assays were performed as described
previously (14).
Statistical analysis
All statistical analysis in this study was done with the
Student’s t-test (http://www.danielsoper.com/statcalc/).
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